Back to top
more

Lantheus (LNTH)

(Delayed Data from NSDQ)

$97.33 USD

97.33
648,582

+0.07 (0.07%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $97.39 +0.06 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Lantheus Holdings (LNTH) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Lantheus Holdings, Inc. (LNTH) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Lantheus Holdings (LNTH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Encompass Health (EHC), Piedmont to Build Loganville Facility

by Zacks Equity Research

Encompass Health (EHC) partners with Piedmont to construct a 40-bed inpatient rehabilitation hospital in Georgia to better serve the rehabilitative care needs of the state and solidify its footprint.

Lantheus Holdings (LNTH) Stock Moves -0.11%: What You Should Know

by Zacks Equity Research

Lantheus Holdings (LNTH) concluded the recent trading session at $62.52, signifying a -0.11% move from its prior day's close.

Is Lantheus (LNTH) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Wall Street Analysts See a 44.13% Upside in Lantheus Holdings (LNTH): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 44.1% in Lantheus Holdings (LNTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See Lantheus Holdings (LNTH) as a Buy: Should You Invest?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Lantheus Holdings (LNTH) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Lantheus' (LNTH) DEFINITY Approved by FDA for Pediatric Use

by Zacks Equity Research

Lantheus' (LNTH) receipt of the expanded indication for DEFINITY is likely to address unmet medical needs of pediatric patients.

Acadia Healthcare (ACHC) Q4 Earnings Beat on Strong Admissions

by Zacks Equity Research

Acadia Healthcare's (ACHC) Q4 results gain on strong growth in revenue per patient day. It expects adjusted EPS of $3.40-$3.70 for 2024, the mid-point of which implies a 3.2% rise from the 2023 reported figure.

Boston Scientific Corporation (BSX) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Boston Scientific (BSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Lantheus Holdings, Inc. (LNTH) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Lantheus Holdings (LNTH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Here's Why You Should Add Lantheus (LNTH) to Your Portfolio

by Zacks Equity Research

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

Lantheus (LNTH) Q4 Earnings Surpass Estimates, Gross Margin Up

by Zacks Equity Research

Lantheus' (LNTH) robust segmental revenues drive its fourth-quarter performance.

Lantheus Holdings (LNTH) Recently Broke Out Above the 50-Day Moving Average

by Zacks Equity Research

Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?

New Strong Buy Stocks for February 23rd

by Zacks Equity Research

IRDM, JSAIY, CAH, LNTH and CENTA have been added to the Zacks Rank #1 (Strong Buy) List on February 23, 2024.

Lantheus Holdings (LNTH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Lantheus Holdings (LNTH) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Lantheus Holdings (LNTH) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 18.24% and 1.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Will TG Therapeutics (TGTX) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts Think Lantheus Holdings (LNTH) Could Surge 58.6%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 58.6% in Lantheus Holdings (LNTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Should You Invest in Lantheus Holdings (LNTH) Based on Bullish Wall Street Views?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Lantheus Holdings (LNTH) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Lantheus (LNTH) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Lantheus' (LNTH) fourth-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.

Lantheus Holdings (LNTH) Falls More Steeply Than Broader Market: What Investors Need to Know

by Zacks Equity Research

In the latest trading session, Lantheus Holdings (LNTH) closed at $57.46, marking a -0.5% move from the previous day.

Lantheus Holdings (LNTH) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Lantheus Holdings (LNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lantheus Holdings (LNTH) Exceeds Market Returns: Some Facts to Consider

by Zacks Equity Research

Lantheus Holdings (LNTH) closed at $55.56 in the latest trading session, marking a +1.76% move from the prior day.

Phibro Animal Health (PAHC) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Phibro (PAHC) delivered earnings and revenue surprises of 22.22% and 2.88%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?